Enalapril vs Angiotensin (1-7) — Peptide Comparison

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

At a Glance

Quickcomparison

Dose Range

Enalapril

2.5 mg–40 mg mg

Angiotensin (1-7)

0.5-1 mcg/kg–5-10 mcg/kg mcg

Frequency

Once daily

Administration

Oral tablet

As directed by healthcare provider

Cycle Length

Ongoing/indefinite

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Strong human trials (Phase 3 or FDA approved)

Moderate human trials (Phase 1-2)

Efficacy

Benefitratings

Cardiovascular Health

Long-term Protection

Quality of Life

Heart Health & Protection

Blood Pressure Balance

Anti-Inflammatory Support

Technical Data

Compoundspecifications

Molecular Formula

C20H28N2O5

Molecular Weight

376.4 g/mol

Half-Life

Enalapril: 1 hour; Enalaprilat (active form): 11 hours effective half-life

Bioavailability

Approximately 60% oral bioavailability when taken by mouth

CAS Number

75847-73-3

C41H62N12O11

899.02 g/mol

Approximately 2-6 hours (varies by route of administration)

Varies by route of administration

25016-41-7

Protocols

Dosingtiers

starting

2.5–5 mg

Titrate over 1–2 weeks

FDA-approved starting dose. For high blood pressure, begin at 5 mg once daily; for heart failure, begin lower at 2.5 mg to avoid a big drop in blood pressure [4].

standard

10–20 mg/day

Once or twice daily

Ongoing

Usual blood-pressure maintenance dose, taken once daily or split into two doses. The dose is raised gradually based on response [4].

advanced

40 mg/day

In two divided doses (20 mg twice daily)

Maximum dose. For heart failure the target is 20 mg twice daily; for high blood pressure up to 40 mg/day is the ceiling [4].

100 mcg/kg

Once daily after each chemotherapy session

Up to 6 chemotherapy cycles

In a cancer trial, this dose was injected under the skin after chemo to help protect platelet counts. A higher 300 mcg/kg dose was also tested but did not work better. [4]

0.5 mg/kg

Up to 10 days

In a COVID-19 study, the lab-made form (called TXA-127) was given as a daily drip into a vein. No serious drug-related side effects were seen. [5]

Applications

Bestsuited for

Managing hypertension to prevent serious complications

Enalapril is particularly well-suited for individuals focused on managing hypertension to prevent serious complications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treating heart failure and improving survival rates

Enalapril is particularly well-suited for individuals focused on treating heart failure and improving survival rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Protecting organs from damage caused by high blood pressure

Enalapril is particularly well-suited for individuals focused on protecting organs from damage caused by high blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Cardiovascular health and heart protection

Angiotensin (1-7) is particularly well-suited for individuals focused on cardiovascular health and heart protection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Blood pressure management and hypertension

Angiotensin (1-7) is particularly well-suited for individuals focused on blood pressure management and hypertension. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Recovery from heart-related conditions

Angiotensin (1-7) is particularly well-suited for individuals focused on recovery from heart-related conditions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-inflammatory support

Angiotensin (1-7) is particularly well-suited for individuals focused on anti-inflammatory support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Dry cough

Dizziness

Fatigue

Hyperkalemia

Angioedema

Serious

Severe allergic reaction

Hypotension (Low Blood Pressure)

Dizziness or Lightheadedness

Injection Site Reactions

Headache

Hyperkalemia (High Potassium)

Research Status

Safety& evidence

FDA Status

FDA approved for this use

Safety Overview

Enalapril is an FDA-approved ACE inhibitor with safety data spanning over 40 years of clinical use and post-market surveillance in millions of hypertensive patients. Persistent dry cough occurs in 10-20% of patients, caused by kinase II inhibition and bradykinin accumulation. Hyperkalemia is a serious risk, particularly in renal impairment, diabetes, or concurrent NSAID/potassium-sparing diuretic use—potassium monitoring is essential. Angioedema (0.1-0.2%) is a rare but life-threatening emergency, absolute contraindication for future ACE inhibitor use. Hypotension can occur in volume-depleted patients or those on concurrent vasodilators. Acute kidney injury risk exists in patients with bilateral renal artery stenosis or single kidney. Fetal teratogenicity is well-documented in pregnancy.

Contraindications

xPregnancy (causes serious fetal harm)

xHistory of angioedema with ACE inhibitors

xSevere renal dysfunction

xConcurrent use with certain other blood pressure medications

xPotassium supplementation without medical supervision

Research compound

Angiotensin (1-7) is not FDA-approved and has no completed human clinical trials, with all safety data limited to animal studies and in vitro mechanistic work. Animal studies suggest potential benefits in hypertension and cardiac remodeling but also reveal risks of hypotension, particularly with concurrent ACE inhibitor or ARB therapy. The peptide's effects on systemic inflammation and immune function in animal models are not validated in humans. No pharmacokinetic data exists defining safe doses, optimal delivery routes, or organ accumulation patterns in humans.

xSevere hypotension or uncontrolled low blood pressure

xAcute myocardial infarction in early stages

xConcurrent use with certain ACE inhibitors without medical supervision

xPregnancy and breastfeeding (insufficient safety data)

Decision Guide

Which isright for you?

Choose Enalapril if...